$AIMAug 3, 2026, 12:33 PMAI processed
AIM says final patient dosed early in Phase 2 DURIPANC; topline expected Q1 2027
AI Summary
AIM ImmunoTech (AIM) announced the final subject received their last dose in the investigator-initiated, single-center Phase 2 DURIPANC study of Ampligen + AstraZeneca’s durvalumab for metastatic pancreatic cancer ahead of schedule; analysis of the primary endpoint (Clinical Benefit Rate at 24 weeks) is set to begin in December 2026 with topline results expected in Q1 2027 and an overall survival analysis due June 2027. AIM highlighted an exploratory Named Patient Program where Ampligen monotherapy showed a median OS of 34.8 vs 12.5 months versus historical controls in an NLR<4.5 biomarker subset and said DURIPANC’s immune profiling could inform a pivotal Phase 3 design.
Positives
- Final subject received last dose ahead of schedule, clearing the trial dosing milestone
- Primary endpoint analysis due to start Dec 2026 with topline results expected in Q1 2027
- Prior Named Patient Program showed a strong OS signal (34.8 vs 12.5 months) in an NLR<4.5 biomarker subset
Negatives
- DURIPANC is an open‑label, single‑center, investigator‑initiated Phase 2, limiting generalizability
- Named Patient Program results were exploratory and used historical controls, not a randomized comparator
- Key efficacy readouts (CBR and OS) are still months away and not yet available